MediciNova
MNOV
35 hedge funds and large institutions have $14.9M invested in MediciNova in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 35 → 35 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.24% less ownership
Funds ownership: 14.19% → 13.96% (-0.24%)
16% less capital invested
Capital invested by funds: $17.6M → $14.9M (-$2.76M)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPAS
Focus Partners Advisor Solutions
Saint Louis,
Missouri
|
+$23.1K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$22.6K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$7.58K |
| 4 |
JP Morgan Chase
New York
|
+$6.25K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$90.9K |
| 2 |
Barclays
London,
United Kingdom
|
-$53K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$51.9K |
| 4 |
B
Bailard
Foster City,
California
|
-$44K |
| 5 |
Renaissance Technologies
New York
|
-$26.2K |
MNOV Hedge Fund Activity: Q3 2022 in Review
35 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in MediciNova (MNOV) for Q3 2022, worth a combined $14.9M — down 16% from $17.6M a quarter earlier.
Fund positioning in MNOV was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 7 added to existing stakes and 15 trimmed.
The largest buyer was Focus Partners Advisor Solutions, opening a new position worth an estimated $23.1K. The largest seller was Susquehanna International Group, cutting an estimated $90.9K.
- 35 institutional investors held MediciNova (MNOV) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $14.9M of MediciNova stock for Q3 2022, down 16% quarter-over-quarter.
- 1 fund opened new MediciNova positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest MediciNova buyer in Q3 2022 was Focus Partners Advisor Solutions, an estimated $23.1K added.
- The largest MediciNova seller in Q3 2022 was Susquehanna International Group, an estimated $90.9K sold.
Based on aggregated 13F filings for Q3 2022.